Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 412 of the 412 references it cites were found in a registry or an index; none of the 354 sources its claims cite is checked for support yet.

The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder

Open access
Turner, Daniel, Briken, Peer, Grubbs, Joshua, Malandain, Leo, Mestre-Bach, Gemma, Potenza, Marc N., Thibaut, Florence·2022·Dialogues in Clinical Neuroscience

Abstract

OBJECTIVES: The current guidelines aim to evaluate the role of pharmacological agents in the treatment of patients with compulsive sexual behaviour disorder (CSBD). They are intended for use in clinical practice by clinicians who treat patients with CSBD. METHODS: An extensive literature search was conducted using the English-language-literature indexed on PubMed and Google Scholar without time limit, supplemented by other sources, including published reviews. RESULTS: Each treatment recommendation was evaluated with respect to the strength of evidence for its efficacy, safety, tolerability, and feasibility. Psychoeducation and psychotherapy are first-choice treatments and should always be conducted. The type of medication recommended depended mainly on the intensity of CSBD and comorbid sexual and psychiatric disorders. There are few randomised controlled trials. Although no medications carry formal indications for CSBD, selective-serotonin-reuptake-inhibitors and naltrexone currently constitute the most relevant pharmacological treatments for the treatment of CSBD. In cases of CSBD with comorbid paraphilic disorders, hormonal agents may be indicated, and one should refer to previously published guidelines on the treatment of adults with paraphilic disorders. Specific recommendations are also proposed in case of chemsex behaviour associated with CSBD. CONCLUSIONS: An algorithm is proposed with different levels of treatment for different categories of patients with CSBD.

Overview

CoChat Summary

TL;DR

The WFSBP guidelines evaluate pharmacological treatment for compulsive sexual behaviour disorder (CSBD), concluding that psychoeducation and psychotherapy are first-choice and should always be conducted. SSRIs and naltrexone are currently the most relevant off-label pharmacological treatments, with hormonal agents reserved mainly for CSBD with comorbid paraphilic disorders and specific recommendations for chemsex-associated CSBD.

Key findings

  • Psychoeducation and psychotherapy are first-choice treatments and should always be conducted; there are few randomised controlled trials, and no medications carry formal indications for CSBD.
  • SSRIs and naltrexone currently constitute the most relevant pharmacological treatments for CSBD, each supported by level B evidence; recommended dose ranges include naltrexone 50–200 mg/day and SSRIs at OCD-like doses (e.g., sertraline 50–200 mg/day, fluoxetine 20–80 mg/day, paroxetine 20–60 mg/day).
  • In CSBD with comorbid paraphilic disorders, hormonal agents may be indicated: cyproterone acetate (level C1) and GnRH agonists (level C3) should be reserved for intense CSBD symptoms with co-occurring paraphilic disorders and at least moderate or high risk of sexual offending.
  • The first placebo-controlled RCT (Lew-Starowicz et al. 2022; n = 73 heterosexual men) found self-reported CSBD severity decreased across paroxetine, naltrexone, and placebo with no between-group differences; clinical interviews found paroxetine and naltrexone more effective than placebo, and craving for sexual encounters and pornography viewing was reduced only in the paroxetine condition.

Methods

  • Literature search used PubMed and Google Scholar without time limit, with keywords including hypersexual, sexual addiction, compulsive sexual behaviour, impulsive sexual behaviour, paraphilia AND medication, antiandrogens, antidepressants, SSRI, naltrexone, cyproterone acetate, medroxyprogesterone acetate, pharmacological, LHRH agonist, and GnRH agonists, supplemented by other sources including published reviews.
  • Studies were included if they contained original data on treatment effectiveness of any pharmacological agent in individuals with non-paraphilic CSB; studies reporting only on patients with paraphilic CSB were excluded because they were covered in the 2020 WFSBP guidelines on paraphilic disorders, though those studies and chemsex studies were referenced.
  • Each treatment recommendation was evaluated for strength of evidence for efficacy, safety, tolerability, and feasibility, and an algorithm was proposed with different treatment levels for different categories of patients with CSBD.

Limitations

  • Stated: most reports on CSBD treatment are case reports or series; treatment efficacy studies have methodological biases; standardised and reliable measures of sexual behaviour are difficult; self-reports are usually used but are not reliable indices; controlled and randomised pharmacological studies are scarce and almost absent in women; comparisons between studies are difficult due to methodological differences.
  • Stated: specific problems may occur when randomisation is adapted to psychological treatments, as therapists may significantly impact outcomes and controlled designs may not facilitate productive therapist–patient relationships.
  • Evident: the authors describe these as “pragmatic guidelines” with less rigorous methodological standards than most WFSBP guidelines due to limited resources and randomised controlled studies, and many recommendations are off-label or based on low-level evidence such as case reports, small samples, and lack of controlled studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/19585969.2022.2134739

Cites

412 of 412 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 8 Not valid · 279 Not checked · 92 Own results and interpretations

196 more claims

Create a free account to see all 379 claims and to verify the 354 references still open.

See all claims — free account
  • It may state two separate claims as one. 127
  • Probably not a substantial claim. 66
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 411 references

Research works printed but not linked: 9

  1. Briken P, Turner D. 2021. Pharmacotherapy for patients with CSBD. In: Compulsive sexual behavior disorder. Washington (DC): American Psychiatric Association Publishing; p. 95–108.
  2. Carnes P. 1989. Contrary to love: Helping the sexual addict. Minneapolis, MN: CompCare.
  3. 10.1080/10720162.2013.772873 · doi:10.1080/10720162.2013.772873
  4. Ciocca G, Nimbi FM, Limoncin E, Mollaioli D, Marchetti D, Verrocchio MC, Simonelli C, Jannini EA, Fontanesi L. 2020. Italian validation of the Hypersexual Behavior Inventory (HBI): psychometric characteristics of a self-report tool evaluating a psychopathological facet of sexual behavior. J Psychopathol. 26:169–175.
  5. Hayden D. 2013. Total sex addiction recovery: a guide to therapy. Bloomington (IN): Xlibris US.
  6. Hergüner S, Hergüner A, Cicek E. 2012. Combination of risperidone and paroxetine for inappropriate sexual behaviors in an adolescent with autism and mental retardation. Arch Neuropsychiatry. 49:311–313.
  7. Rösler M, Retz W, Turner D. 2020. Pharmacotherapy of ADHD in adults. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. NeuroPsychopharmacotherapy. Cham: Springer International Publishing; p. 1–18.
  8. Savard J. 2021. Compulsive sexual behavior disorder: clinical characteristics and treatment with Naltrexone [dissertation]. Umeå: Umeå University.
  9. Stekel W. 2013. Onanie und Homosexualität: Die homosexuelle Neurose [Onanism and homosexuality. The homosexual neurosis]. Bremen: Bremen University Press

Cited by

See all 86

Metadata

Authors
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F.
Affiliations
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Bowling Green State University (US)
  • Department of Psychiatry and Addictive Disorders, University Hospital Cochin (site Tarnier) AP-HP, Paris, France
  • Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja, La Rioja, Spain
  • Yale University (US)
  • Inserm (FR)
Corresponding author
  • Turner, Daniel
  • Thibaut, Florence
Venue
Dialogues in Clinical Neuroscience
Published
2022-11-17
Volume
24
Issue
1
Pages
10-69
ISSN
  • 1294-8322 (ISSN-L)
  • 1958-5969
OpenAlex
W4309426955
Cited by
86
References
411
Citations by year
2026: 28 · 2025: 25 · 2024: 16 · 2023: 14 · 2022: 2
FWCI
13.00
Type
journal article
Language
en
Open access
Locations
  • Dialogues in Clinical Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • Re-Unir (International University of La Rioja) (submittedVersion, other-oa)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
Keywords
pharmacotherapy, selective serotonin reuptake inhibitors, naltrexone, paraphilic disorders, chemsex, hormone therapy, psychoeducation, psychotherapy, treatment algorithm, psychiatric comorbidity
MeSH terms
Adult, Biological Psychiatry, Compulsive Behavior, Humans, Paraphilic Disorders, Sexual Behavior, Sexual Dysfunctions, Psychological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. https://app.cochat.ai/papers/10.1080/19585969.2022.2134739
The paper
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022). The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. Dialogues in Clinical Neuroscience. https://doi.org/10.1080/19585969.2022.2134739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.